JP2011504474A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011504474A5 JP2011504474A5 JP2010534409A JP2010534409A JP2011504474A5 JP 2011504474 A5 JP2011504474 A5 JP 2011504474A5 JP 2010534409 A JP2010534409 A JP 2010534409A JP 2010534409 A JP2010534409 A JP 2010534409A JP 2011504474 A5 JP2011504474 A5 JP 2011504474A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- disease
- medicament
- inhibitor
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07022695 | 2007-11-22 | ||
| PCT/EP2008/009880 WO2009065596A2 (en) | 2007-11-22 | 2008-11-21 | Use of mnk inhibitors for the treatment of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011504474A JP2011504474A (ja) | 2011-02-10 |
| JP2011504474A5 true JP2011504474A5 (enExample) | 2011-12-22 |
Family
ID=40404966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534409A Pending JP2011504474A (ja) | 2007-11-22 | 2008-11-21 | アルツハイマー氏病を治療するためのＭｎｋインヒビターの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100247517A1 (enExample) |
| EP (1) | EP2219649A2 (enExample) |
| JP (1) | JP2011504474A (enExample) |
| CA (1) | CA2706203A1 (enExample) |
| WO (1) | WO2009065596A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5301986B2 (ja) * | 2005-06-22 | 2013-09-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物用のチエノピリミジン類 |
| JP5302883B2 (ja) * | 2006-04-07 | 2013-10-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物用のｍｎｋ１／ｍｎｋ２阻害活性を有するチエノピリミジン |
| EP1889847A1 (en) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| US8877186B2 (en) * | 2007-06-06 | 2014-11-04 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
| WO2010023181A1 (en) | 2008-08-26 | 2010-03-04 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
| MX2012009735A (es) * | 2010-02-26 | 2012-09-12 | Boehringer Ingelheim Int | 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas. |
| UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| BR112012021453A2 (pt) * | 2010-02-26 | 2017-02-21 | Boehringer Ingelheim Int | tienopirimidina, sua composição farmacêutica e seu uso |
| ES2649995T3 (es) | 2011-07-18 | 2018-01-16 | Merck Patent Gmbh | Benzamidas |
| US9868744B2 (en) | 2014-04-25 | 2018-01-16 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
| GB201520500D0 (en) * | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| GB201520499D0 (en) * | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| DK3582776T3 (da) | 2017-02-14 | 2024-01-08 | Effector Therapeutics Inc | Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder |
| KR20210102211A (ko) | 2018-10-24 | 2021-08-19 | 이펙터 테라퓨틱스, 인크. | Mnk 억제제의 결정질 형태 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW444018B (en) * | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
| EP0729758A3 (en) * | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases |
| GB9906566D0 (en) * | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
| US7419978B2 (en) * | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| CA2551689A1 (en) * | 2004-01-05 | 2005-07-28 | Merz Pharma Gmbh & Co. Kgaa | Memantine for the treatment of mild and mild-to-moderate alzheimer's disease |
| GB0412467D0 (en) * | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| EP1746099A1 (en) * | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 inhibitors |
| JP5301986B2 (ja) * | 2005-06-22 | 2013-09-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物用のチエノピリミジン類 |
| WO2007059905A2 (en) * | 2005-11-25 | 2007-05-31 | Develogen Aktiengesellschaft | Thienopyrimidines treating inflammatory diseases |
| RU2489155C2 (ru) * | 2006-03-29 | 2013-08-10 | Велакор Терапеутикс Пти Лтд | Лечение нейродегенеративных заболеваний |
| FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
| JP5302883B2 (ja) * | 2006-04-07 | 2013-10-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物用のｍｎｋ１／ｍｎｋ２阻害活性を有するチエノピリミジン |
| US20080107755A1 (en) * | 2006-04-24 | 2008-05-08 | Alltech, Inc. | Methods and compositions for altering cell function |
| ATE456565T1 (de) * | 2006-06-22 | 2010-02-15 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren |
-
2008
- 2008-11-21 US US12/744,374 patent/US20100247517A1/en not_active Abandoned
- 2008-11-21 WO PCT/EP2008/009880 patent/WO2009065596A2/en not_active Ceased
- 2008-11-21 CA CA2706203A patent/CA2706203A1/en not_active Abandoned
- 2008-11-21 EP EP08852675A patent/EP2219649A2/en not_active Withdrawn
- 2008-11-21 JP JP2010534409A patent/JP2011504474A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011504474A5 (enExample) | ||
| JP5657556B2 (ja) | α７選択的リガンドを用いる治療 | |
| IL191311A (en) | Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| HK1198619A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX2014002460A (es) | Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso. | |
| EP2279727A3 (en) | Nanoparticulate aripiprazole formulations | |
| JP2010535801A5 (enExample) | ||
| JP2012508734A5 (enExample) | ||
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| WO2007136518A3 (en) | Treatment of autoimmune disorders | |
| JP2015520221A5 (enExample) | ||
| CY1105507T1 (el) | Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες | |
| RU2013154699A (ru) | Сцилло-инозитол для применения в лечении поведенческих и психических расстройств | |
| JP2015500223A5 (enExample) | ||
| JP2016510343A5 (enExample) | ||
| JP2012531402A5 (enExample) | ||
| WO2007096396A3 (en) | Methods for treating autoimmune or demyelinating diseases | |
| WO2009003694A3 (en) | Method for treating diseases related to mitochondrial dysfunction | |
| JP2009178162A5 (enExample) | ||
| JP2020527172A5 (enExample) | ||
| WO2014047288A3 (en) | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2018529747A5 (enExample) | ||
| JP2010526884A5 (enExample) |